Plain-English translation of NCT05303714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining standard chemotherapy with PIPAC (a procedure where chemotherapy medicine is sprayed directly into the abdomen during a minimally invasive surgery) works better than chemotherapy alone for people with stomach cancer that has spread to the abdominal lining. Half of the participants will receive standard chemotherapy only, and the other half will receive standard chemotherapy plus the PIPAC procedure. Researchers want to see if this combination approach helps patients live longer and have better outcomes.
Stomach cancer that spreads to the abdominal lining is difficult to treat and has a poor outlook with chemotherapy alone. This trial exists to find out whether delivering chemotherapy directly to the affected area through this minimally invasive procedure can improve survival and give patients better treatment options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first undergo a diagnostic laparoscopy to confirm the extent of your cancer. Then you will be randomly assigned to one of two groups: one receiving 6 courses of standard chemotherapy, or the other receiving the same 6 courses of chemotherapy plus the PIPAC procedure three times throughout your treatment. Throughout the trial, you will have regular CT scans, blood tests, and potentially another laparoscopy to see how well the treatment is working. The trial lasts several months, with follow-up visits at a participating hospital center.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy